- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03477240
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
A Cross-Sectional Feasibility Study of a Telephonic Questionnaire By Research Nurses For Follow-Up Of Locally Advanced Cervical Cancer Patients With Complete Response To Treatment.
Studieoversikt
Status
Detaljert beskrivelse
Our institution registers on an average 670 cases of cancer cervix in a year and almost 75% are treated with curative intent, therefore around 500 patients a year would be treated with curative intent. Assuming that 75% of patients registered in a year would be receiving treatment at our institute, 375 patients a year would be completing treatment, of whom the investigator expect 80-85% ,i.e 300 patients to have a complete response. The list of patients who have completed radio(chemotherapy) in 2015 &2016 can be obtained from the Radiation Oncology Department records. Patients identified for a follow up visit will be telephonically contacted between one and two weeks before the planned clinic visit and verbal telephonic consent taken prior to the nurse-led interview. This study should be able to accrue 300 patients in 6 months.
Patients of locally advanced cervical cancer or vault cancer who have been treated with radiotherapy with or without concurrent chemotherapy and have a clinical complete response at 3 months post treatment and are within the first 2 years post treatment completion will be eligible to participate in this study.
Screening: Patients will be screened from the list of patients treated in the radiotherapy department over the last 2 years (2015-2016), available from the Radiation Oncology Information System (ROIS). All patients with a diagnosis of cervical cancer or vault cancer will be screened using the hospital Electronic Medical Record (EMR) to check stage of disease, schedule of treatment received, response at 3 months post treatment and expected date of next follow up.
If patient fulfils all inclusion criteria, she will be called by the research nurse, approximately 1-2 weeks prior to her expected date of follow up, for a preliminary conversation and invited to participate in the study.
After verbal telephonic consent is obtained, she will be interviewed by the clinical research nurse using the format of the prepared proforma (Form A) regarding symptoms suggestive of disease recurrence as well as treatment induced toxicity. At the end of the interview, the research nurse records her impression of whether the patient has worrisome symptoms of disease or not and has symptoms of treatment toxicity or not for which she should visit the hospital.
When the patient reports to the OPD the next week for scheduled physical follow up, the nurse completes the consenting process by taking a short written informed consent. The examining physician then takes a complete history and in addition, performs a physical examination and any investigations he/she deems necessary. Following this he/she notes down final impression of disease status and toxicity which are taken as the gold standard (Form B). Each patient will be interviewed only once during their follow up schedule.
In addition at the physical visit, information regarding the acceptability of nurse-led telephonic follow-up to the patient and the financial impact of physical follow- up will be collected using a structured format (Form C).
Study participant drop-out/ Lost-to-follow up: Patients may withdraw their consent at any point during the telephonic interview or the subsequent follow up visit.
- A patient who does not attend the scheduled follow up visit within 1-2 weeks of the telephonic interview will be called a second time to remind her of the follow up appointment and enquire about reasons for non-attendance in the clinic, which will be recorded. If patient does not report to the clinic within the next 2 weeks, she will be considered to have dropped out from the study.
- Those patients in whom the interval between telephonic interview and the physician's assessment is more than 4 weeks, will be considered drop outs and follow up telephone call will go out to enquire about reasons for non-attendance in the clinic, which will be recorded.
Studietype
Registrering (Forventet)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Cervical Cancer Stage Ib2, II and III (Squamous carcinoma or adenocarcinoma)
- Cancer of the vault
- Cancer of the cervix which inadvertently underwent hysterectomy (inadequate surgery)
- Treated with curative intent with radical radio(chemo)therapy or NACT followed by radical radio(chemo)therapy and completed all curative treatment.
- Within 2 years post completion of treatment
- Has complete clinical response at 3 months post treatment
- Informed consent
- Contactable by telephone
Exclusion Criteria:
- Patients with Stage III disease treated with palliative intent with once monthly radiotherapy
- Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors
- Metastatic cervical cancers
- Patients who are unable to comprehend the questions or dialogue over telephone by medical staff.
- Patients who seem unreliable for follow up
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of nurse-led telephonic interview for disease recurrence
Tidsramme: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of disease recurrence, in terms of sensitivity and specificity values
|
1 YEAR
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accuracy of nurse-led telephonic interview for late toxicity of treatment
Tidsramme: 1 YEAR
|
To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of late toxicity of treatment
|
1 YEAR
|
|
Acceptability of a nurse-led telephonic surveillance program using structured format (Form C).
Tidsramme: 1 YEAR
|
To assess patients' acceptability of a nurse-led telephonic surveillance program (if found to be concordant with physical clinic visits)
|
1 YEAR
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- TMH-1950
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Livmorhalskreft stadium IIIB
-
National Cancer Institute (NCI)FullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical plateepitelkarsinom | Tilbakevendende livmorhalskreft | Stadium IVA Livmorhalskreft | Stadium IVB Livmorhalskreft | Stadium IIIA Livmorhalskreft | Stadium IIIB LivmorhalskreftCanada
-
National Cancer Institute (NCI)NRG OncologyFullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical plateepitelkarsinom | Stadium IB2 Livmorhalskreft AJCC v8 | Stadium II Livmorhalskreft AJCC v8 | Stadium IIA Livmorhalskreft AJCC v8 | Stadium IIA1 Livmorhalskreft AJCC v8 | Stadium IIA2 Livmorhalskreft AJCC v8 | Stadium IIB Livmorhalskreft... og andre forholdForente stater
-
National Cancer Institute (NCI)NRG OncologyFullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stadium IB2 Livmorhalskreft AJCC v6 og v7 | Stadium II Livmorhalskreft AJCC v7 | Stadium IIA Livmorhalskreft AJCC v7 | Stadium IIB Livmorhalskreft AJCC v6 og v7 | Stadium IIIB... og andre forholdForente stater
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UkjentCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stadium IIA Livmorhalskreft AJCC v7 | Stadium IIB Livmorhalskreft AJCC v6 og v7 | Stadium IIIB Livmorhalskreft AJCC v6 og v7 | Stage IVA Livmorhalskreft AJCC v6 og v7 | Stadium... og andre forholdForente stater
-
GOG FoundationNational Cancer Institute (NCI)FullførtCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stadium IIA Livmorhalskreft AJCC v7 | Stadium IIB Livmorhalskreft AJCC v6 og v7 | Stadium IIIB Livmorhalskreft AJCC v6 og v7 | Stage IVA Livmorhalskreft AJCC v6 og v7 | Stadium...Forente stater, Canada, Saudi-Arabia, Kina, Singapore
-
University of WashingtonNational Cancer Institute (NCI); National Institutes of Health (NIH)AvsluttetCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Tilbakevendende livmorhalskreft | Cervikal udifferensiert karsinom | Stadium IIA Livmorhalskreft | Stadium IIB Livmorhalskreft | Stadium III Livmorhalskreft | Stadium IVA Livmorhalskreft og andre forholdForente stater, Hong Kong, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtGastroøsofageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Spiserørskreft AJCC v7 | Stadium IIIA Spiserørskreft AJCC v7 | Stadium IIIB Spiserørskreft AJCC v7 | Stage IIIC esophageal cancer AJCC v7 | Ondartet neoplasma i cervical esophagus | Ondartet neoplasma i thoraxøsofagusForente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeAvansert vaginalt adenokarsinom | Avansert vaginalt adenoskvamøst karsinom | Avansert vaginal plateepitelkarsinom | Stadium IB2 Livmorhalskreft AJCC v6 og v7 | Stadium II Livmorhalskreft AJCC v7 | Fase II Vaginal Cancer AJCC v6 og v7 | Fase III Vaginal Cancer AJCC v6 og v7 | Stadium IIIB Livmorhalskreft... og andre forholdForente stater
-
National Cancer Institute (NCI)NRG OncologyAktiv, ikke rekrutterendeCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Avansert vaginalt adenokarsinom | Avansert vaginalt adenoskvamøst karsinom | Avansert vaginal plateepitelkarsinom | Cervical plateepitelkarsinom | Stadium IB2 Livmorhalskreft AJCC v6 og v7 | Stadium II Livmorhalskreft AJCC v7 | Fase II Vaginal... og andre forholdForente stater, Canada, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Livmorhalsplateepitelkarsinom, ikke spesifisert på annen måte | Stadium IB3 Livmorhalskreft FIGO 2018 | Fase II Livmorhalskreft FIGO 2018 | Stadium IIA Livmorhalskreft FIGO 2018 | Stadium IIA1 Livmorhalskreft FIGO 2018 | Stadium IIA2 Livmorhalskreft... og andre forholdForente stater